kneat.com, inc. announced it has signed a three-year SaaS Master Services Agreement with Fresenius Kabi Germany, a leading supplier of clinical nutrition, infusions, pharmaceuticals and medical technology. The agreement is effective immediately and allows the company to scale Kneat across all its business divisions and affiliates. With more than 3,500 branded products, and its own logistics and decentralized supply centers, Fresenius Kabi continuously improves its processes to supply clinics, pharmacies, medical practices, dealers, care facilities and patients at home with trusted therapies.

By deploying Kneat's offering to digitize the validation of its production equipment, facilities and utilities, Fresenius Kabi continues its path to even greater operational efficiencies and data integrity for these validation processes. This Agreement marks Kneat's first engagement with Fresenius Kabi, which employs more than 41,000 people worldwide. Fresenius Kabi is an independent subsidiary of Fresenius, a more than 300,000-employee global healthcare group.

Kneat's demonstrated track record of delivering a strong ROI to its life sciences customers positions Kneat to scale to multiple manufacturing sites and processes across Fresenius Kabi. The initial deployment is across five sites for validating production equipment, facilities and utilities. Implementation will commence in Quarter 1 2023, with an expected go-live date in Quarter 2 2023.

Separately, earlier this month, one of Kneat's largest pharmaceutical customers and one of its few remaining on-premise deployments signed a three-year master agreement to transition to a SaaS deployment, easing the way for further expansion over the coming years. The customer expects to complete its transition in Quarter 2 2023.